Table 3.

Vaccine protection against infection with BA.5 or BA.2 in Denmark, by vaccine status

	Infected with BA.5 during the outcome period	Infected with BA.2 during the outcome period	OR	Adjusted OR*
Three doses versus unvaccinated
Three doses†	9307 (94·2%)	30 581 (94·8%)	0·90 (0·82–0·99)	1·18 (0·99–1·42)
Unvaccinated	571 (5·8%)	1691 (5·2%)	1	1
Three doses versus two doses
Three doses†	9307 (94·8%)	30 581 (95·3%)	0·90 (0·81–1·00)	1·12 (0·92–1·35)
Two doses‡	513 (5·2%)	1515 (4·7%)	1	1

Data are n (%) or OR (95% CI). All participants were infected with SARS-CoV-2 omicron subvariants BA.5 or BA.2. The outcome period was April 10–June 30, 2022. The analysis included individuals with or without a previous SARS-CoV-2 infection before the start of the outcome period.

^*Adjusted for age group, time of infection (week number), sex, region of residence, comorbidities, and previous infection (yes vs no).

^†Received three doses of either mRNA-1273 (lasomeran, Moderna) or BNT162b2 (tozinameran, Pfizer-BioNtech) before March 27, 2022.

^‡Completed primary vaccination series more than 140 days before the start of the outcome period.